Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-blind, Placebo-controlled, Phase 3 Multicenter Study to Evaluate the Safety and Efficacy of Abaloparatide-SC for the Treatment of Men With Osteoporosis

Trial Profile

A Randomized, Double-blind, Placebo-controlled, Phase 3 Multicenter Study to Evaluate the Safety and Efficacy of Abaloparatide-SC for the Treatment of Men With Osteoporosis

Recruiting
Phase of Trial: Phase III

Latest Information Update: 24 Oct 2018

At a glance

  • Drugs Abaloparatide (Primary)
  • Indications Male osteoporosis
  • Focus Registrational; Therapeutic Use
  • Acronyms ATOM
  • Sponsors Radius Health Inc.
  • Most Recent Events

    • 10 May 2018 According to Radius media release, if this study is successful, the data will form the basis of a supplemental NDA seeking to expand TYMLOS label.
    • 30 Mar 2018 Status changed from planning to recruiting, according to a Radius Health media release.
    • 21 Nov 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top